Who Supplies Amiodarone to India from UNITED KINGDOM

To import finished pharmaceutical formulations containing Amiodarone into India, the Central Drugs Standard Control Organization (CDSCO) mandates that the importer obtain an Import Registration and License as per the Drugs and Cosmetics Act and Rules. This requirement ensures that imported drugs meet the necessary quality, safety, and efficacy standards. The registration process involves submitting an application to CDSCO, providing detailed product information, and obtaining approval before importation. The timeline for import drug registration can vary, but it typically involves thorough evaluation and may take several months. For formulations under HS Code 30049099, specific documentation and compliance with CDSCO guidelines are essential for successful importation.

Imported pharmaceutical formulations containing Amiodarone must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required to ensure each batch meets the prescribed standards. A Certificate of Analysis (CoA) is mandatory, detailing the product's composition and compliance with quality standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's stability under Indian climatic conditions. The Indian Pharmacopoeia standards serve as the benchmark for quality assessment. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

Between 2024 and 2026, the CDSCO has implemented regulatory updates to streamline the import process for pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. Bilateral agreements between India and the United Kingdom have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), thereby enhancing the efficiency of pharmaceutical imports.

India imports finished Amiodarone formulations primarily due to the availability of patented or branded products, specific dosage forms, and formulations not produced domestically. The domestic capacity for manufacturing certain Amiodarone formulations is limited, leading to a reliance on imports to meet patient needs. The market size for Amiodarone in India is substantial, with a significant volume of imports to satisfy the demand for this critical medication.

The import duty structure for Amiodarone formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per the prevailing rates, which are subject to change. There are no specific exemptions or concessional duties for imports from the United Kingdom under this HS code. The total landed duty percentage varies based on the IGST rate and other applicable charges.

India sources Amiodarone formulations from the United Kingdom due to the availability of patented formulations, specialized dosage forms, and high-quality products. The United Kingdom's pharmaceutical industry is known for its stringent quality standards and innovative formulations, providing a competitive advantage in the Indian market. Other suppliers, such as China, Germany, and the United States, also contribute to India's Amiodarone imports, but the United Kingdom maintains a significant share due to its established trade relations and product offerings.

India imports Amiodarone formulations from the United Kingdom due to the availability of patented formulations, specialized dosage forms, and high-quality products not produced domestically. The United Kingdom's pharmaceutical industry offers innovative formulations and stringent quality standards, making it a preferred source for these formulations. Specific formulations, such as certain strengths or delivery methods, may not be manufactured in India, necessitating imports to meet patient needs.

When compared to other origins like China, Germany, and the United States, the United Kingdom offers competitive advantages in terms of product quality, regulatory compliance, and reliability. The United Kingdom's adherence to high manufacturing standards and its established trade relations with India contribute to its unique position in supplying Amiodarone formulations. While other countries may offer lower prices, the United Kingdom's consistent quality and compliance with international standards make it a preferred choice for Indian importers.

Indian importers face several supply chain risks when sourcing Amiodarone formulations from the United Kingdom, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or logistical challenges. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, and maintain robust quality assurance processes.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO, including submission of Form 40/41.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics